Rezolute (RZLT) Capital Expenditures (2013 - 2022)

Rezolute (RZLT) reported Capital Expenditures of $83000.0 for Q4 2022, up 18.57% sequentially from $70000.0 in Q3 2022.

Rezolute (RZLT) Capital Expenditures (2013 - 2022) Analysis & Trends

Rezolute (RZLT) has 8 years of Capital Expenditures data on file, last reported at $83000.0 in Q4 2022.

For the quarter ending Q4 2022, Capital Expenditures changed N/A year-over-year to $83000.0; the trailing twelve-month figure through Jun 2023 stood at $153000.0 (changed N/A YoY), and the FY2023 full-year result was $153000.0, changed N/A from the prior year.
Capital Expenditures advanced to $83000.0 in Q4 2022, from $70000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $83000.0 in Q4 2022 to a low of $184.0 in Q2 2018.
A 3-year average of $40036.8 and a median of $41000.0 in 2019 frame the typical range for Capital Expenditures.
Across the five-year window, Capital Expenditures plunged 99.83% in 2018 and soared 3160.87% in 2019, its largest moves.
Tracing RZLT's Capital Expenditures over 3 years: stood at $184.0 in 2018, then soared by 3160.87% to $6000.0 in 2019, then soared by 1283.33% to $83000.0 in 2022.
Business Quant data shows RZLT's Capital Expenditures at $83000.0 in Q4 2022, $70000.0 in Q3 2022, and $6000.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Rezolute	31,153.77	31,153.77	-	-

Download Data